ArticleAnnals of surgical oncology2026
Mesenteric Peritonectomy as the Seventh Peritonectomy Technique in Cytoreductive Surgery for Peritoneal Surface Malignancies: A Propensity Score-Matched Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenteric involvement represents a major challenge in cytoreductive surgery (CRS) for peritoneal surface malignancies, historically regarded as a relative contraindication to complete cytoreduction. Mesenteric peritonectomy (MP), first described by Deraco et al. in 2009, selectively removes the peritoneal layer at the bowel-mesentery interface. Despite growing interest in its clinical application, robust outcome data from comparative studies remain lacking.
methodsThis retrospective, single-center study included 391 consecutive patients undergoing CRS-hyperthermic intraperitoneal chemotherapy at Fondazione IRCCS Istituto Tumori di Milano (2016-2024). MP was classified as partial, subtotal, or total. The primary endpoint was major postoperative morbidity (National Cancer Institute Common Terminology Criteria for Adverse Events grade ≥3); secondary endpoints included operative time, small bowel resections, completeness of cytoreduction, Comprehensive Complication Index, length of hospital stay, reoperation rate, and in-hospital mortality. A 1:1 propensity score-matched analysis compared subtotal/total MP patients with controls.
resultsMP was performed in 76 patients (19.4%), predominantly for diffuse malignant peritoneal mesothelioma and serous papillary peritoneal carcinoma. In the matched cohort (n = 28 per group), MP was not associated with increased major morbidity (odds ratio 1.06; 95% confidence interval 0.37-3.06, p = 0.91), Comprehensive Complication Index, length of hospital stay, or reoperation rate. MP was associated with a longer operative time (+63 min; p = 0.005) and a higher likelihood of small bowel resection (odds ratio 6.4; 95% confidence interval 2.7-15.2; p < 0.001). No in-hospital deaths occurred in the MP group.
conclusionsMP was a safe extension of CRS, as reflected by the high rate of complete cytoreduction. Despite increased surgical complexity, it was not associated with a significant increase in major morbidity, supporting its adoption at experienced centers.
Indexed as
Identifiers
42726355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.